Why Is Merck Stock Trading Higher On Monday?

On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality. PAH is high blood pressure in pulmonary arteries, which carry oxygen-poor blood from the heart to the lungs. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening-related hospitaliz ...